You are here: Industry Insights > gene therapy

News List

REGENXBIO Doses First Patient in RGX-111 Trial for Mucopolysaccharidosis Type I Treatment americanpharmaceuticalreview
December 16, 2020
REGENXBIO announced the first patient has been dosed in the Phase I/II trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I).
Passage Bio, Catalent Begin cGMP Mfg. for Gene Therapies contractpharma
December 11, 2020
Completion of dedicated cGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS product candidates.
Neurogene announces EMA grants orphan drug designation for aspartylglucosaminuria gene therapy pharmaceutical-business-review
December 09, 2020
Neurogene announces that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria.
Janssen buys rights to Hemera’s eye disease gene therapy candidate pharmatimes
December 04, 2020
Johnson & Johnson’s pharmaceuticals division Janssen has purchased rights to acquire an investigational gene therapy asset for geographic atrophy from Hemera Biosciences.
Cytovance Expands Partnership with Nature Technology Corp. contractpharma
December 04, 2020
Now offers NTC’s proprietary HyperGRO manufacturing platform for plasmid DNA CGMP manufacturing.
PhoreMost, Oxford Biomedica Announce Gene Therapy Discovery Collaboration americanpharmaceuticalreview
November 18, 2020
PhoreMost and Oxford Biomedica have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
Seelos Announces Patent for SLS-007 americanpharmaceuticalreview
November 02, 2020
Seelos Therapeutics has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007.
CEVEC, Rznomics Ink License Agreement for CAP Technology contractpharma
October 22, 2020
Rznomics will use CEVEC’s cell line technology with its trans-splicing ribozyme technology for manufacturing gene therapies targeting various cancers.
Roche signs deal with Dyno Therapeutics for gene therapy vectors pharmatimes
October 16, 2020
Roche has signed a collaborative agreement with Dyno Therapeutics for the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) disease and liver-directed therapies.
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B contractpharma
October 16, 2020
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page